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Radionuclide therapy (RNT), also known as “targeted”, “metabolic” or “molecular” 
radiotherapy uses open (i.e. “unsealed”) radioactive isotopes, generally administered orally 
or intravenously, enabling the delivery of a high radiation dose to the target, while 
minimising normal-tissue toxicity. This systemic form of radiation therapy has distinct 
similarities, but also profound differences as compared to the more commonly used 
external beam radiotherapy (EBRT). From another perspective, RNT can be better 
characterised as a tumour-selective treatment modality with more similarities to systemic 
chemotherapy [1]. 
The amount of transferred energy in joules per unit mass (Kg) of target tissue is expressed in 
grays (Gy); 1 Gy = 1J/Kg. This absorbed radiation dose unit is also employed in EBRT.Actually, 
the term “radiation dose” covers three kinds of dose: “absorbed dose” expressed in mGy 
indicating the amount of energy deposited by radiation in a mass, “equivalent dose” 
(absorbed Dose x the appropriate radiation weighting factor in function of the type of 
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radiation; e.g. ,,  or neutrons) expressed in mSv to an organ and “effective dose” (sum 
of equivalent doses to all organs, each adjusted with the appropriate tissue weighting 
factor; taking in account the sensitivity of the organ to radiation) expressed in mSv for the 
whole body. The 3 kinds of radiation dose should not be confounded with the frequently 
used term, in the context of radionuclide therapy, “activity dose” that refers to the 
administered activity expressed in MBq. 
While CT can be used for relatively straightforward calculation of the absorbed dose in 
EBRT, in RNT the spatial and temporal distribution of radiation, within the time interval of 
the decaying isotope, is extremely complex, depending on a highly dynamic interplay of 
pharmacokinetics aspects (such as perfusion, metabolism, target expression heterogeneity, 
transmembrane cellular uptake, intracellular degradation, radionuclide release, and 
excretion), repair mechanisms and radiobiological phenomena (low and continuously 
decreasing dose rate).  
In order to estimate the local absorbed dose, integral activities rely on accurate detection of 
the activity distribution over time. However, due to the limited spatial resolution of imaging 
devices, calculations are based on approximation and it is important to note that it is not 
possible to perform the “perfect” dosimetry study. To date, the need for and added value of 
dosimetry to optimise the therapeutic activity dose for the individual patient has been far 
from self-evident. RNT dosimetry has not gained wide acceptance as a clinical tool in the 
nuclear medicine community because of an imbalance between the lack of accuracy and the 
complexity of time-consuming and costly procedures, potentially posing a significant burden 
to our patients and our health care systems. Moreover, the necessary specialised knowledge 
and experience required to perform accurate dosimetry studies is not available in all clinical 
centres, therefore potentially limiting the offer to patients. A number of clinical studies have 
completely refrained from dosimetry, instead using fixed activities for all patients or 
individualised activity doses based on body weight or body surface area. Indeed, after seven 
decades of treating thyroid cancer patients, international guidelines still do not provide an 
unequivocal recommendation on the amount of radioiodine that should be given [1]. 
For those reasons, rather than seeking similarities to EBRT, it is more appropriate to develop 
RNT similar to chemotherapeutics, where dose calculation based on body weight or body 
surface area is common practice, independent of the tumour load and metastases. The 
maximal tolerated dose of chemotherapeutics is established during clinical studies. In 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
subsequent clinical practice, the level of chemotherapeutic in blood is not checked to 
investigate the biodistribution and the delivery to the tumours. 
Official guidelines and recommendations for RNT do not include advanced dosimetric 
calculations. Like in the chemotherapy, fixed radioactivity doses (with or without visual 
assessment of pretherapy scans) or body weight or body surface area based activity doses 
are considered sufficient in clinical practice for the main clinical RNT protocols. 
Nevertheless, the European Council Directive 2013/59 [2], to be translated into national 
legislations before 6 February 2018, stipulates that in medical exposures for 
radiotherapeutic purposes, including RNT, exposures of target volumes shall be individually 
planned and their delivery appropriately verified.  
In a recent article published in this Journal, Chiesa et al. [3] pointed out this aspect. While 
these authors recognize that in RNT “the absorbed dose to the target volume cannot be 
calculated or reliably predicted for technical or practical reasons”, a solution “to base 
therapy planning on the maximum tolerable absorbed dose (MTAD) to nontarget organs or 
tissues” is advocated. The authors do not explain why the nontarget solution is more 
feasible than target calculations, since the dosimetric procedures appear similar, hampered 
by the same errors of measurement (except for the evaluation of the irradiated volume) and 
by identical logistical issues. As these authors pointed out, dosimetry in disseminated 
disease is difficult and in many cases not possible. In RNT, maximal absorbed dose to 
tumours or metastases is required, but the activity dose is restricted by the absorbed dose 
to critical normal organs (e.g. kidney and bone marrow in peptide radionuclide therapy) to 
avoid irreversible deterministic effects. Furthermore, the strategy to individually calculate 
the maximum tolerated dose for normal organs with the goal to enhance therapeutic 
efficacy assumes that 1. the dose will increase in a therapeutically relevant manner in all 
lesions and 2. that the dose always predicts the outcome. Both assumptions ignore biology. 
The local dose depends not only on the administered activity but also on the expression of 
the target in tumor lesions which often show a high intralesional as well as interlesional 
heterogeneity. As stated above the efficacy of RNT is determined by pharmacokinetics and 
repair mechanisms. Since RNT is often applied in patients at later stages and after various 
treatments we face tumors with increased heterogeneity and optimized escape strategies. 
In our opinion, dosimetry should be a quantitative procedure that unequivocally provides 
additional clinical benefit over standard procedures to the individual patients. Dosimetry 
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should play an important role when a new agent for RNT undergoes clinical testing, 
alongside assessment of the maximum tolerated dose and of side-effects, similar to clinical 
trials of non-radioactive oncological drugs. In the clinical setting, the statement of DeNardo 
et al. [4] postulated more than 15 years ago is still valid: “claims for specific dosimetry have 
to demonstrate that the frequency of excess toxicity and/or tumour underdosing 
significantly decreases”. From a clinical point of view, dosimetry studies could be considered 
in current daily clinical practice when treating patients with risk factors [5]. 
Another important factor is represented by radiobiological effects of RNT at the cellular and 
molecular level [6]. Extrapolations made from EBRT are wrong, due to the fundamental 
differences in dose rate and mechanisms of inflicting damage to the DNA. In RNT, with its 
decreasing dose rate, tumour DNA repair takes place simultaneously with sublethal damage 
[7]. Furthermore, it was recently reported that sensitivity to low-absorbed dose, low-dose 
rate radiation displays a genetically-induced individual variability. [8, 9]. 
 
In conclusion, although dosimetry is an undisputed aspect of radiopharmaceutical 
development, its clinical use to tailor the administered activity to an individual patient’s 
needs is less evident. Data in the literature clearly and unequivocally establishing the 
potential of dosimetry to avoid under- and overdosing and to standardise radionuclide 
therapy methods are very scarce. Furthermore, dosimetry is a difficult procedure that is not 
available everywhere as specialised knowledge and experience are required. Thus, we must 
be cautious before transferring complex dosimetry to routine clinical practice, while robust 
scientific justification remains to be established. First and foremost, the nuclear medicine 
community at large has the obligation to prove in prospective and randomised trials with 
adequate methodology, that complex dosimetry-based radionuclide therapy has clinically 
relevant additional benefits for our patients over the currently used, well-established and 
very safe empiric dosing methods, whether using fixed-activity concepts or based on simple 
characteristics such as body weight and body surface area.  
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